News

LATEST NEWS

Newronika News & Articles

Newronika, il servizio del TG1 Medicina

Newronika Appoints Keith Carlton as Executive Chairman to Reinforce Strategic Leadership

Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease

Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System

Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform

New treatment prospects for people with Parkinson's thanks to international research funded by the Michael J. Fox Foundation for Parkinson's Research

Newronika Sercures Initial €2 Million in Blended Finance from EIC Accelerator for Groundbreaking Parkinson’s Disease Research

Newronika Secures 2.5 Million Euros Grant From EIC Accelerator

Round d’investimento da 8,4 milioni per Newronika

Medtech, la startup italiana Newronika chiude un round da 8,4 milioni

Newronika Raises an 8.4M EUR Series-A Round

Fondo Intesa Sanpaolo investe in Newronika

Innogest e Intesa investono 1,7M in Newronika (Deep Brain Stimulation)

Newronika chiude un round di venture capital

Innogest, Intesa Sanpaolo e F3F investono 1,7 milioni in Newronika

Neuromodulation Therapy Developer Newronika Raises €1.7M in Venture Capital

Newronica, 1,7 milioni per la startup che combatte il Parkinson

È italiano il primo pacemaker intelligente per il Parkinson

Join Our Journey

Setting the new standard of care together.

Partner with Newronika to bring the next generation of adaptive brain therapy to patients who need it most.

Contact Us

Let’s talk.

Whether you’re a clinician, researcher, investor, or partner — we’d love to hear from you.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

This device is CE-marked and commercially available in the European Economic Area. In the United States, the device is investigational and limited by federal law to investigational use only. It has not been cleared or approved by the U.S. Food and Drug Administration.